Eris Lifesciences on Wednesday reported 39 percent year-on-year (YoY) rise in quarterly net profit to Rs 134 crore in Q2FY26 led by its branded formulations business.
Revenue rose 6.9 percent YoY to Rs.792 crore. EBITDA rose 8.8 percent YoY to Rs.288 crore, while EBITDA margin rose 65 basis points to 36.4%, up 65 basis points.
Net debt stood at Rs 2,278 crore as of September 30.
The domestic branded formulation business reported revenue growth of 10% YoY in Q2 FY26. Chairman & MD Amit Bakshi said the company’s branded formulations business grew 10% YoY in Q2, outperforming the market by over 30%. “We expect tailwinds in H2 from insulin cartridge opportunities and price increases. GLP-1 launch readiness is on track,” he added.
“The Biocon business has seen a sharp turnaround, with margins rising to 32% in Q2 from 19% at the time of acquisition," said Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer said.
"The Swiss Parenterals business acquired in 2024 is on the threshold of significant transformation with FY27 set to be a breakout year," Vaidyanathan added.
Vaidyanathan said the company plans to invest Rs 380–400 crore in capital expenditure over the next three quarters to support expansion and capacity enhancement in our diabetes-obesity and general injectables businesses.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
